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Abstract 
Background: Profilin sensitisation is considered a diagnostic confounding factor in areas where patients are exposed 
to multiple pollens. The aim of this study is to assess pollen sensitisation profiles in adults and children and to evalu-
ate, by means of component-resolved diagnosis (CRD) and skin prick testing (SPT), which pollens may be considered 
as risk factors of profilin sensitisation in order to establish the best diagnostic approach in polysensitised patients.
Methods: A total of 231 pollen-allergic patients (adults and children) were included, out of the pollen season, from 
an area with similar levels of pollen exposure. Allergological diagnosis was performed by SPT and determination of 
specific IgE (sIgE) to major allergen components (ADVIA-Centaur™). Patients had not received immunotherapy in the 
last 5 years and had to reside in the area for 5 consecutive years before entering the study.
Results: The relation between sensitisation measured by SPT and by sIgE was studied using a model of cases 
(patients with +sIgE to a specific allergen) and controls (patients with −sIgE to the same allergen). The outcome, 
in terms of odds-ratios (OR), was statistically significant for Olea (Ole e 1) (p = 0.0005), Salsola (Sal k 1) (p = 0.0118) 
and Platanus (Pla a 1+ 2) (p = 0.0372). While positivity of SPT to most pollens was statistically associated with a risk 
of profilin sensitisation, by CRD the association was statistically significant only for Ole e 1 (OR 3.5, CI 95 %, 1.6–7.6, 
p = 0.0014), and Phl p 5 (OR 11.9, CI 95 %, 4.1–35.2, p < 0.001). When analysing this association using a logistic regres-
sion model, Phl p 5 was the only allergen associated with the risk of being sensitised to profilin (p = 0.0023).
Conclusions: In patients sensitised to profilin, the concordance between SPT and CRD is much lower than in those 
not sensitised to profilin. CRD is able to provide refined information about which pollens increase the risk of sensitisa-
tion to profilin.
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Background
Immunoglobulin E (IgE)-mediated allergic diseases, 
mainly asthma and allergic rhinitis, are highly prevalent 
diseases, affecting hundreds of millions of people world-
wide [1, 2]. The inherent costs of these diseases, espe-
cially in developed countries, are extremely high [3, 4]. 
Therefore, defining an adequate diagnostic strategy is 
crucial in order to establish the best therapeutic option 
and consequently, reduce the economic burden of aller-
gic diseases. Until recently, the allergological diagnosis 
in clinical practice was mainly based on the IgE response 
against whole allergen extracts, either assessed by means 
of skin prick test (SPT) and/or by specific IgE (sIgE). 
However, the sensitisation profile of allergic patients 
in complex pollen areas reveals that most patients are 
polysensitised [5]. In these patients, the use of conven-
tional techniques may result insufficient to establish an 
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frequently polysensitisation may be due to cross-reac-
tivity caused by sensitisation to panallergens, such as 
profilin, polcalcin or lipid-transfer proteins [7, 8]. Sensi-
tisation to these molecules makes it difficult to discern 
whether a positive test to a whole extract, either by SPT 
or sIgE, is positive due to a primary sensitisation or a 
cross-reactivity phenomenon.
Component-resolved diagnosis (CRD) provides a more 
specific diagnosis in patients with positive IgE to mul-
tiple pollen allergens. The main outcome is to learn the 
sensitisation profile of allergic patients and consequently, 
to allow a more precise prescription of immunotherapy 
including only relevant allergens [9, 10].
Some of the aforementioned studies have been per-
formed with patients from different geographical areas 
and consequently, with different sensitisation profiles as 
well as different allergen exposure. Therefore, extrapolat-
ing conclusions, although valid, may entail certain bias [5, 
7]. In our study we have analysed allergic patients from 
one geographical area, with the aim of (a) establishing 
the sensitisation profiles in the selected area to the more 
prevalent aeroallergens by means of SPT and CRD as 
well as the differences in these profiles according to age, 
type of allergic respiratory disease and presence of plant-
food allergy, (b) studying the differences between both 
diagnostic techniques in patients sensitised to the main 
panallergen in the area (profilin) and (c) in profilin-sen-
sitised patients, establishing the risk-factors associated 
with being sensitised to profilin.
Methods
Geographical area of study
The study has been carried out in a geographical area 
(Aragon, Spain) with a continental Mediterranean cli-
mate with cold winters, dry and hot summers and with 
areas of high mountains (see Fig. 1).
Patients
Patients included in the study were selected consecutively 
for two periods in the same year before and after the pol-
len season. All patients had a clinical history of seasonal 
allergic rhinitis, rhinoconjunctivitis or asthma for at least 
2 years, should not have received immunotherapy in the 
last 5 years, according to the same methodology used in 
previous studies [5, 7] and had to reside in the area of 
the study for 5 consecutive years or longer before being 
included in the study.
Clinical diagnosis of allergic rhinitis and asthma was 
performed according to international and national guide-
lines [11, 12].
Written informed consent was obtained from each 
patient before entering the study. In case of patients aged 
<18  years, informed consent of parents/guardians was 
also obtained. The study was approved by the regional 
ethical committee (Comité Etico de Investigación Clínica 
de Aragón).
Serum samples were collected from the subjects, stored 
at −40 °C and thawed immediately before analysis.
Skin prick test extracts
Natural profilin, Pho d 2 extract, was prepared by purify-
ing a date palm extract by affinity chromatography with a 
poly-l-proline-Sepharose. Purity (higher than 99 %) was 
checked by SDS-PAGE, mass spectrometry and amino 
acid analysis. The concentration of Pho d 2 in the extract 
was 50 µg/ml. Date palm polcalcin enriched extract was 
obtained from the same extract (showing total protein 
concentration of 500  µg/ml after Lowry) after removal 
of profilin. In a previous experiment, positive SPT 
responses to complete Palm tree extracts were assigned 
either to profilin or polcalcin sensitised patients, but 
not to LTPs, CCDs or Glucanases. Protein identity was 
assessed by SDS-PAGE. The concentration of polcalcin, 
measured by an inhibition assay against r-Che a 3, was 
determined to be 1 µg/ml.
A commercial peach extract from ALK-Abello S.A., 
adjusted to 30 µg/ml of Pru p 3, was shown to lack other 
relevant allergens (such as Pru p 1 and Pru p 4).
The other diagnostic extracts used in the study (Olea, 
grass-mix, Artemisia, Salsola, Cupressus, Parietaria, Pla-
tanus and Plantago) were complete commercial extracts 
from ALK-Abello S.A. at 30  HEP/ml. Alternaria extract 
is standardised in μg/mL of the major allergen Alt a 1 (25 
μg/mL). These pollens were selected because they are the 
most prevalent sensitizing allergens in the area.
Fig. 1 Geographical area of the study
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Panel of purified allergens for sIgE determination to major 
allergens
The panel of allergens included in the study were: nPhl p 
1 and nPhl p 5, nOle e 1, nArt v 1, nCup s 1, nPar j 2, nPla 
a 1+ 2, nPla l 1, nSal k 1. The panallergens studied were: 
nPho d 2 (profilin), rChe a 3 (polcalcin) and rPru p 3 
(LTP). sIgE against Alt a 1 was also determined due to the 
clinical relevance of this allergen in the area, not studied 
in previous research [7] and also because the exposure to 
grass and Alternaria may be linked to severe asthma [24].
The manufacturing process of all these allergens has 
been previously described [5, 7, 13].
Specific IgE to the different allergens was tested with 
the ADVIA Centaur® platform (Bayer HealthCare Diag-
nostics Division, Tarrytown, NY, USA). The principle of 
the sIgE assay is based upon a reverse sandwich assay and 
was performed according to previously established meth-
ods [14].
Specific IgE was considered positive when ≥0.35 kU/l.
Statistical methods
In order to analyse qualitative variable association, Pear-
son’s Chi square test was used when variables fitted all 
required assumptions and Fisher’s exact test when not. A 
multivariate analysis by means of logistical regression by 
determination of the odds ratio was used to evaluate the 
level of risk of being sensitised to profilin.
Results
Sample description
A total of 231 patients were included in the study. 
Patients characteristics are described in Table  1. The 
mean (SD) age of patients was 22.6 (13.6) years, median 
(range): 18 (4–65)  years. Despite food allergy not being 
an inclusion criterion, almost 20 % of patients had aller-
gic food reactions.
Sensitisation profiles
In Fig. 2a, b we can see the sensitisation rates by SPT and 
sIgE to major allergens. The statistically significant dif-
ferences on the sensitisation profile according to demo-
graphic and clinical parameters studied are shown in 
Table 2. 
The percentage of patients sensitised to Alternaria was 
23 % by SPT and 24 % by sIgE to its major allergen Alt a 
1.
Comparison of results in patients sensitised to profilin
Patients sensitised to profilin were sensitised to a higher 
number of allergen sources, when compared to profilin-
negative patients; this was true, both for SPT (mean of 
9  allergens vs. 5 allergens, p  <  0.0001) and sIgE (mean of 
4 allergens vs. 2 allergens, p < 0.0001). In both groups, the 
relation between sensitization measured by SPT and by sIgE 
was studied by means of a study of cases (patients with posi-
tive sIgE to a specific allergen) and controls (patients with 
negative sIgE to the same allergen). The outcome, in terms of 
odds-ratios (OR), was statistically significant for Olea (Ole e 
1), Salsola (Sal k 1) and Platanus (Pla a 1+ 2) (Table 3) indi-
cating that concordance between both diagnostic techniques 
is much higher for patients not sensitised to profilin.
The risk of being sensitised to profilin was assessed for 
SPT and sIgE results. For SPT, different pollens are statis-
tically associated with the risk of being sensitised to this 
panallergen (Olea p = 0.04, Grass p = 0.0006, Artemisia 
p = 0.0135, Salsola p = 0.0044, Platanus p < 0.0001 and 
Plantago p  <  0.0001). However, when this risk is ana-
lysed considering the sIgE (>0.35 kU/l) despite SPT, the 
only allergens associated with risk are Ole e 1 (OR 3.5, CI 
95 %, 1.6–7.6, p = 0.0014), and Phl p 5 (OR 11.9, CI 95 %, 
4.1–35.2, p < 0001). Applying a logistic regression model, 
the only allergen with a statistically significant risk is Phl 
p 5 (p =  0.0023). Analysing this OR for different levels 
of sIgE to Phl p 5, the risk decreases but remains statis-
tically significant (sIgE > 10 kU/l: OR 7.6, CI 95 %: 3.3–
35.2, p < 0001. sIgE > 50 kU/L: OR 5.2, CI 95 %: 2.4–11.3, 
p < 0001).
Table 1 Characteristics of patients
%
Age
 ≤14 years 45.9








  Mild intermittent 63.0
  Mild persistent 25.9
  Moderate 11.1
Food allergy 18.7
 Oral allergy syndrome (OAS) 13.4
  Fruits 5.2
  Nut 3.5
  Fruits and nut 3.0
  Seafood 1.3
 Urticaria/angioedema 7.8
  Fruits 3.0
  Nut 2.6
 Anaphylaxis 1.3
 Asthma 0.4
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Food allergy
The presence of food allergy is associated with differ-
ent allergens depending on the clinical reaction. Oral 
allergy syndrome (OAS) as the only clinical manifestation 
of food allergy was statistically associated with differ-
ent allergens by SPT (Artemisia, p  <  0.0001: Parietaria, 
p = 0.0121: Platanus, p = 0.0045, peach, p < 0.0001 and 
profilin, p  =  0.0290) and by sIgE (Phl p 5, p  =  0.0478 
and Pru p 3, p < 0.0001, being close to statistical signifi-
cance for Art v 1, p = 0.0661 and Pho d 2, p = 0.0801). 
However, when the clinical manifestation of food allergy 
was more severe (urticaria, angioedema, anaphylaxis) 
the association for SPT results is only significant for 
Artemisia (p  =  0.0118) and peach (p  <  0.0001) and by 
sIgE, only for Pru p 3 (p < 0.0001).
Discussion
Nowadays, to perform a diagnostic workup of allergic dis-
eases based only on conventional techniques such as SPT 
or sIgE to whole extracts may result insufficient in many 
patients. Allergic patients frequently present sensitisation 
to multiple allergens, both children [15] and adults, and it 
is not always possible to establish which allergens are posi-
tive due to genuine sensitization or which allergens are posi-
tive due to a phenomenon of cross-reactivity. CRD has been 
















































Fig. 2 Prevalence of major allergens measured by SPT and sIgE, a Pollens and Alternaria, b panallergens
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diagnostic tool, not only for establishing the sensitisation 
profile of patients but also because it may aid in selecting the 
most adequate composition of allergen immunotherapy.
Many recent publications have pointed out the role of 
panallergens as a confusion factor for the correct diag-
nosis of allergic sensitization [5, 7, 8, 21]. Therefore, the 
diagnostic algorithm in complex allergen areas must take 
into account the sensitisation (or not) to these allergens. 
Several diagnostic algorithms have been proposed [7, 9].
In this study, when we compare the adult and paediat-
ric populations, we see that both conventional diagnostic 
techniques and CRD perform similarly. Alternaria sensi-
tization is more prevalent in children than in adults, both 
by SPT and CRD. Previous studies, or studies in which 
sensitisation to Alternaria is a risk factor in the adult pop-
ulation for severe asthma [23], have shown that humidity 
and fungi such as Alternaria are associated with a greater 
sensitisation rate in the infant population aged 5–6 years 
[22]. In this study, this kind of association was not 
observed, probably due to the type of patient included.. 
Only sensitisation to Sal k 1 appears to be associated 
with a distinct clinical expression, being more prevalent 
in patients with rhinitis than in those with asthma. Dif-
ferences were observed between results obtained by SPT 
and those obtained by CRD in patients with food allergy. 
Whereas there are different allergens associated with the 
presence of OAS by SPT, probably due to the presence of 
lipid-transfer proteins (LTPs) in these extracts, by CRD 
we see that OAS is associated with sensitisation to two 
allergens (Phl p 5 and Pru p 3), while severe reactions are 
associated exclusively with Pru p 3. The model of patients 
with pollinosis and food allergy is complex, although its 
study allows us to gain insight to some characteristics of 
allergic sensitization and clinical reactivity.
The confounding effect of sensitisation to profilin on 
the interpretation of diagnostic techniques has already 
been highlighted in previous studies conducted accord-
ing to a methodology similar to our own [5, 7]. Through 
a case–control study, we can see that in patients sensi-
tised to the major allergens of Olea, Salsola and Plata-
nus, the concordance of SPT and CRD is much greater 
in the absence of profilin sensitization. In the case of 
sensitisation to Phl p 5, the differences were almost sta-
tistically significant (p = 0.067); no significant differences 
were recorded for the remaining allergens. These results 
may indicate that profilin sensitization is related with the 
most prevalent pollens in the area of study, and conse-
quently with higher clinical relevance, excluding Plantago 
(high prevalence by SPT but low prevalence of sensitiza-
tion to its major allergen Pla l 1) and Cupressus. The lack 
of relation between sensitization to cypress-pollen and 
profilin has been previously observed [25]. When assess-
ing the risk of sensitisation to profilin, by SPT, multiple 
allergens are associated with this risk (grass, Olea, Sal-
sola, Artemisia, Platanus and Plantago) and it is difficult 
Table 2 Differences on  sensitisation profile according 
to demographic and clinical parameters
The figures correspond to percentage of patients with a positive test (SPT or 
sIgE). Only statistical significant results are displayed




 Alternaria 32.1 15.2 0.0024
 Cupressus 32.1 48.8 0.0100
 Polcalcin 16 25.6 0.0498
sIgE+
 Alt a 1 35 14.8 0.0004




 Peach 35 14.8 0.0034
sIgE+








 Artemisia 58.1 21 <0.0001
 Parietaria 26.8 10 0.0121
 Platanus 51.6 26.5 0.0045
 Peach extract 45.2 9.5 <0.0001
 Profilin 32.3 16 0.0290
sIgE+
 Phl p 5 64.5 45.4 0.0478
 Pru p 3 54.8 11.8 <0.0001




 Artemisia 58.1 23.6 0.0118
 Peach extract 61.3 9.1 <0.0001
sIgE+
 Pru p 3 69.6 11.8 <0.0001
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to establish which one is the culprit pollen. However, 
when we determine this risk measuring the sensitisation 
to major allergens by means of CRD, the association is 
only statistically significant for the two more prevalent 
allergens: Ole e 1 and Phl p 5. However, unlike in other 
studies where there are areas with very high grass aller-
gen concentrations [5], the risk of sensitisation to profilin 
not only increases in line with IgE values, which, in turn, 
increase in response to Phl p 5, but the OR value actu-
ally decreases. This difference is probably attributable to 
the fact that grasses are the most prevalent allergen in the 
area studied, though there are other allergens (Olea, Sal-
sola and Cupressus) that are also relevant where there is 
no one visibly dominant pollen.
Conclusion
Panallergen sensitization is a major confounder factor 
when using conventional diagnostic techniques (whole 
extract SPT or sIgE). CRD is an essential tool for deter-
mining the risk-factors associated with panallergen sensi-
tisation, allowing to overcome these pitfalls.
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